Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 12, 2015 - Issue 12
Submit an article Journal homepage
328
Views
26
CrossRef citations to date
0
Altmetric
Original Research

How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis

Marcello Moccia“Federico II” University, Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Naples, Italy+39 08 17 46 37 64; +39 08 15 46 36 63; [email protected]
,
Raffaele PalladinoDepartment of Primary Care and Public Health, Imperial College, London, UK;Federico II University, Department of Public Health, Naples, Italy
,
Cinzia Russo“Federico II” University, Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Naples, Italy+39 08 17 46 37 64; +39 08 15 46 36 63; [email protected]
,
Marco Massarelli“Federico II” University, Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Naples, Italy+39 08 17 46 37 64; +39 08 15 46 36 63; [email protected]
,
Antonio NardoneFederico II University, Department of Public Health, Naples, Italy
,
Maria TriassiFederico II University, Department of Public Health, Naples, Italy
,
Alessandra Lugaresi“Gabriele d’Annunzio” University of Chieti-Pescara, Department of Neuroscience, Imaging and Clinical Sciences, Chieti, Italy
&
Vincenzo Brescia Morra“Federico II” University, Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Naples, Italy+39 08 17 46 37 64; +39 08 15 46 36 63; [email protected]
 show all
Pages 1829-1835 | Published online: 15 Sep 2015

Bibliography

  • Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663–74
  • Hupperts R, Ghazi-Visser L, Martins Silva A, et al. The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis. Clin Ther 2014;36:1946–57
  • WHO. Adherence to long-term therapies. Evidence for Action; Genva, Switzerland: 2003
  • Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart® injection device. Patient Prefer Adherence 2014;8:843–51
  • Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother 2014;14:1029–42
  • Fernández O, Agüera J, Izquierdo G, et al. Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. PLoS One 2012;7:1–7
  • Zettl UK, Bauer-Steinhusen U, Glaser T, et al. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. BMC Neurol 2013;13:117
  • Steinberg SC, Faris RJ, Chang CF, et al. Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis. Clin Drug Investig 2010;30:89–100
  • Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proceedings 2011;86:304–14
  • Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568–76
  • Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292–302
  • Coyle PK, Cohen BA, Leist T, et al. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol 2014;14:49
  • Patti F. Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Prefer Adherence 2010;4:1–9
  • EMA. European public assessment reports. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
  • Lugaresi A. RebiSmartTM (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv 2013;10:273–83
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014;83:278–86
  • Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261–7
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52
  • Exell S, Verdum E, Driebergen A. A new electronic device for subcutaneous injection of IFN-β-1a. Expert Rev Med Devices 2011;8:543–53
  • Murray MD, Harrison J. Prescription abandonment: Another path to medication nonadherence. Ann Intern Med 2010;153:680–1
  • Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurol 2012;11:33–41
  • Van Walraven C, Hart RG. Leave ’em alone - Why continuous variables should be analyzed as such. Neuroepidemiology 2008;30:138–9
  • Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3–14
  • Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69–77
  • Lanzillo R, Moccia M, Carotenuto A, et al. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. Mult Scler 2015;21(9):1215–16
  • Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res 2013;11:54–65

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.